Statement Of Changes In Equity [Abstract]

Transgene - Filing #2813436

Concept 2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
As at
2020-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity
50 628 EUR
32 804 EUR
808,000 EUR
450,000 EUR
70 813 EUR
50 102 EUR
37 841 EUR
19 536 EUR
2 933 EUR
31 092 EUR
1 423 EUR
67 209 EUR
67 441 EUR
48 886 EUR
50 716 EUR
41 921 EUR
1 051 EUR
17 231 EUR
13 861 EUR
39 212 EUR
1 726 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)
- EUR
- EUR
32 804 EUR
- EUR
- EUR
32 804 EUR
32 804 EUR
- EUR
- EUR
19 536 EUR
- EUR
19 536 EUR
- EUR
- EUR
- EUR
19 536 EUR
Other comprehensive income
973,000 EUR
372,000 EUR
Comprehensive income
- EUR
- EUR
31 831 EUR
- EUR
973,000 EUR
32 804 EUR
31 831 EUR
- EUR
- EUR
19 908 EUR
372,000 EUR
19 536 EUR
- EUR
- EUR
- EUR
19 908 EUR
Issue of equity
- EUR
- EUR
- EUR
- EUR
- EUR
- EUR
- EUR
- EUR
33 342 EUR
- EUR
- EUR
- EUR
26 377 EUR
6 965 EUR
Increase (decrease) through treasury share transactions, equity
- EUR
212,000 EUR
- EUR
- EUR
- EUR
212,000 EUR
- EUR
57,000 EUR
57,000 EUR
- EUR
- EUR
- EUR
- EUR
- EUR
Increase (decrease) through share-based payment transactions, equity
- EUR
- EUR
- EUR
- EUR
- EUR
2 675 EUR
2 675 EUR
- EUR
3 002 EUR
- EUR
- EUR
- EUR
3 002 EUR
- EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.